
Skip this Video
Durability of Effect in Double-blind Phase Item Active treatment Placebo value P 25% of patients had LTR By day 34 By day 7 <0.0001 LTR by end of study 32% of patients 61% of patients <0.0001 Worsening fatigue (MAF By day 119 By day 27 <0.0001 scale) Worsening in Overall Sleep Problems Index By day 42 By day 14 <0.0001 (MOS - sleep scale) Presented at EULAR 2007.